Natural Product (NP) Details

General Information of the NP (ID: NP0050)
Name
Phenethyl isothiocyanate
Synonyms
2-Phenylethyl isothiocyanate; Phenethyl isothiocyanate; 2257-09-2; Phenylethyl isothiocyanate; (2-Isothiocyanatoethyl)benzene; Phenethyl mustard oil; Benzene, (2-isothiocyanatoethyl)-; Phenylaethylsenfoel; 2-isothiocyanatoethylbenzene; PEITC; Phenylethyl mustard oil; PHENETHYLISOTHIOCYANATE; phenethyl-isothiocyanate; 2-phenethyl isothiocyanate; 2-phenylethylisothiocyanate; ISOTHIOCYANIC ACID, PHENETHYL ESTER; beta-Phenethyl isothiocyanate; MFCD00004821; beta-Phenylethyl isothiocyanate; CHEBI:351346; NSC 87868; UNII-6U7TFK75KV; 6U7TFK75KV; CHEMBL151649; .beta.-Phenethyl isothiocyanate; 1-Isothiocyanato-2-phenylethane; .beta.-Phenylethyl isothiocyanate; 1-(2-isothiocyanatoethyl)benzene; (2-Isothiocyanato-ethyl)-benzene; Isothiocyanic Acid 2-Phenylethyl Ester; 2-phenylethanisothiocyanate; Phenylaethylsenfoel [German]; 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4); CCRIS 3146; EINECS 218-855-5; BRN 2084162; ACMC-1CLKQ; DSSTox_CID_1120; WLN: SCN2R; beta-phenethylisothiocyanate; ss-Phenethyl isothiocyanate; Epitope ID:138724; b-phenylethyl isothiocyanate; DSSTox_RID_75951; DSSTox_GSID_21120; 2-phenyl ethyl isothiocyanate; SCHEMBL156960; Phenethyl isothiocyanate, 99%; DTXSID5021120; IZJDOKYDEWTZSO-UHFFFAOYSA-; (2-Isothiocyanatoethyl)benzene #; 2-Phenylethyl isothiocyanate, FG; HMS1783C17; HMS3870G13; NSC87868; ZINC2022074; Tox21_200100; (2-Isothiocyanatoethyl)benzene, 9CI; ANW-13714; BBL009999; BDBM50240850; NSC-87868; SBB002732; STK397325; AKOS000119469; DB12695; JC-5411; MCULE-7681211375; NE22461; Isothiocyanic acid beta-phenylethyl ester; NCGC00248526-01; NCGC00257654-01; AC-12769; AS-17373; BP-12941; NCI60_041942; U800; CAS-2257-09-2; DB-045947; Isothiocyanic acid .beta.-phenylethyl ester; FT-0604634; P0986; Phenethyl isothiocyanate, analytical standard; ST50330661; 4-12-00-02476 (Beilstein Handbook Reference); A816267; J-802164; Q7181339; W-107466; BRD-K56700933-001-02-1; F0001-0795
    Click to Show/Hide
Species Origin Nasturtium officinale ...     Click to Show/Hide
Nasturtium officinale
Kingdom: Viridiplantae
Phylum: Streptophyta
Class: Magnoliopsida
Order: Brassicales
Family: Brassicaceae
Genus: Nasturtium
Species: Nasturtium officinale
Disease Prostate cancer [ICD-11: 2C82] Phase 2 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.551
 
MDCK Permeability
 -4.576
 
PAMPA
 - - -
 
HIA
 - - -
 
Distribution
VDss
 -0.069
 
PPB
 97.9%
 
BBB
 - -
 
Metabolism
CYP1A2 inhibitor
 ++
CYP1A2 substrate
 ++
CYP2C19 inhibitor
 - -
CYP2C19 substrate
 - -
CYP2C9 inhibitor
 - -
CYP2C9 substrate
 - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 - - -
CYP3A4 inhibitor
 +++
CYP3A4 substrate
 +++
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 +++
CYP2C8 inhibitor
 ++
HLM Stability
 -
 
Excretion
CLplasma
 10.134
 
T1/2
 2.136
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 +
 
FDAMDD
 +++
 
Respiratory
 +++
 
Human Hepatotoxicity
 - - -
 
Ototoxicity
 - - -
 
Drug-induced Nephrotoxicity
 - - -
 
Drug-induced Neurotoxicity
 +
 
Hematotoxicity
 - - -
 
Genotoxicity
 - - -
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C9H9NS
PubChem CID
16741
Canonical SMILES
C1=CC=C(C=C1)CCN=C=S
InChI
1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2
InChIKey
IZJDOKYDEWTZSO-UHFFFAOYSA-N
CAS Number
CAS 2257-09-2
ChEBI ID
CHEBI:351346
Herb ID
HBIN039468
TTD Drug ID
D07AOL
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Dibenzoylmethane      Solid tumour/cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Molecule(s)
                    Regulation		 Down-regulation Phosphorylation AKT1  Molecule Info 
Pathway MAP
Down-regulation Expression BIRC5  Molecule Info 
Pathway MAP
Down-regulation Activity p105  Molecule Info 
Pathway MAP
                    In-vitro Model DU145 CVCL_0105 Prostate carcinoma Homo sapiens
PC-3 CVCL_0035 Prostate carcinoma Homo sapiens
VCaP CVCL_2235 Prostate carcinoma Homo sapiens
                    In-vivo Model For a xenograft model, 2 * 106 VCaP cells per 0.1 ml suspended in a mixture of Matrigel and RPMI 1640 medium (1 : 1) were injected subcutaneously into the back of the mice.
                    Experimental
                    Result(s)		 Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgenindependent growth of prostate cancer cells.
          Cisplatin      Bladder cancer     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [3]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    Biological
                    Regulation		 Up-regulation ROS generation
                    In-vitro Model Meso4 CVCL_H678 Pleural epithelioid mesothelioma Homo sapiens
Meso11 CVCL_H670 Pleural epithelioid mesothelioma Homo sapiens
Meso13 CVCL_H672 Pleural epithelioid mesothelioma Homo sapiens
Meso34 CVCL_H675 Pleural epithelioid mesothelioma Homo sapiens
Meso47 CVCL_H680 Pleural epithelioid mesothelioma Homo sapiens
Meso56 CVCL_H681 Pleural epithelioid mesothelioma Homo sapiens
Meso96 CVCL_H683 Pleural epithelioid mesothelioma Homo sapiens
Meso76 cells established from pleural fluids of patients Malignant Pleural Mesothelioma Homo sapiens
Meso152 cells established from pleural fluids of patients Malignant pleural mesothelioma Homo sapiens
                    Experimental
                    Result(s)		 The combination of cisplatin with the natural compound PEITC induces a strong MPM cell death, while remaining safe for PMC, with limited emergence of cell resistance compared to drugs used alone.
References
Reference 1 ClinicalTrials.gov (NCT00691132) Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers. U.S. National Institutes of Health.
Reference 2 Phenethyl isothiocyanate in combination with dibenzoylmethane inhibits the androgen-independent growth of prostate cancer cells. Food Funct. 2018 Apr 25;9(4):2398-2408.
Reference 3 Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma. Oncotarget. 2014 Nov 30;5(22):11641-52.
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link      
 Download Picture         KEGG Link